Curium to Acquire Lantheus for Up to $8 Billion, Expanding Radiopharmaceuticals Presence
Radiopharmaceutical company Curium has agreed to acquire peer firm Lantheus Holdings in a deal valued at up to $8 billion. The transaction includes an upfront cash payment of $102.50 per share for Lantheus shareholders, with potential additional payments based on future sales performance by 2030. This acquisition aims to strengthen Curium's position in the rapidly growing radiopharmaceutical sector. Lantheus is a major player known for its diagnostic imaging agents like Pylarify, used in detecting prostate cancer through PET scans. The deal has drawn regulatory scrutiny due to both companies' significant roles in the market. Analysts have noted that while the upfront offer represents a premium over Lantheus's recent stock price, it may not meet all investor expectations. The transaction is expected to close by mid-2027 and will be financed through debt and equity. The deal reflects broader industry trends of consolidation in radiopharmaceuticals, with other major acquisitions including Bristol Myers Squibb’s purchase of RayzeBio and AstraZeneca's acquisition of Fusion Pharmaceuticals.
Topics: dealmaking healthcare private equity radiopharmaceuticals